| Mr John F Patterson, CRNA | |
|
100 E College Dr, Colby, KS 67701-3702 | |
| (785) 462-7511 | |
| (785) 460-4870 |
| Full Name | Mr John F Patterson |
|---|---|
| Gender | Male |
| Speciality | Nurse Anesthetist, Certified Registered |
| Location | 100 E College Dr, Colby, Kansas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437173135 | NPI | - | NPPES |
| 145139 | Other | KS | BLUE CROSS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 55427 (Kansas) | Primary |
| Entity Name | County Of Logan |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1821087230 PECOS PAC ID: 7719890904 Enrollment ID: O20061104000220 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.
Actor Stephen McGann, who plays GP Dr Patrick Turner in the hit BBC period drama Call the Midwife, has described the steps taken by the writers, production team and actors to ensure the series has sufficient medical accuracy and authenticity. In an essay published today by the Journal of the Royal Society of Medicine, McGann writes of the unique insight that the role of Dr Turner has given him into questions regarding the way popular culture portrays medics and medicine.
Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.
A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer's.
› Verified 4 days ago
| Entity Name | County Of Logan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285629535 PECOS PAC ID: 7719890904 Enrollment ID: O20110602000276 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.
Actor Stephen McGann, who plays GP Dr Patrick Turner in the hit BBC period drama Call the Midwife, has described the steps taken by the writers, production team and actors to ensure the series has sufficient medical accuracy and authenticity. In an essay published today by the Journal of the Royal Society of Medicine, McGann writes of the unique insight that the role of Dr Turner has given him into questions regarding the way popular culture portrays medics and medicine.
Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.
A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer's.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr John F Patterson, CRNA 100 E College Dr, Colby, KS 67701-3702 Ph: (785) 462-7511 | Mr John F Patterson, CRNA 100 E College Dr, Colby, KS 67701-3702 Ph: (785) 462-7511 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced it has submitted additional patent applications, covering its Cobalamin-mediated oral drug delivery technology formulations of many global top-100 injectable drugs, as a result of the growing interest surrounding the company's proprietary oral delivery technology.
Actor Stephen McGann, who plays GP Dr Patrick Turner in the hit BBC period drama Call the Midwife, has described the steps taken by the writers, production team and actors to ensure the series has sufficient medical accuracy and authenticity. In an essay published today by the Journal of the Royal Society of Medicine, McGann writes of the unique insight that the role of Dr Turner has given him into questions regarding the way popular culture portrays medics and medicine.
Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.
Achillion Pharmaceuticals, Inc., a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced the nomination of a lead clinical candidate in its fourth proprietary program against hepatitis C virus (HCV) infection. The candidate, ACH-2928, is an NS5A inhibitor that in preclinical studies has demonstrated excellent potency against HCV RNA replication, as well as good pharmacokinetic and safety profiles.
A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer's.
› Verified 4 days ago
Robert Lee Erwin Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 E College Dr, Colby, KS 67701 Phone: 785-462-7511 Fax: 785-460-9320 |